- Conditions
- Macular Degeneration, Retinal Drusen
- Interventions
- Pascal Retinal Laser Photocoagulator
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Geographic Atrophy
- Interventions
- OCU410
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Prism Vision Group
- Other
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Edison, New Jersey
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,079 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- 24GyE proton and Anti-VEGF, 16GyE and anti-VEGF, Sham Irradiation and anti-VEGF
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Cystoid Macular Edema, Fuchs Dystrophy
- Interventions
- Optical Coherence Tomography
- Diagnostic Test
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Varying needle size with intravitreal ranibizumab or aflibercept
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinal Hemorrhage, Macular Degeneration
- Interventions
- vitrectomy with subretinal lucentis
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Diabetic Macular Edema, Epiretinal Membrane
- Interventions
- Ozurdex
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Macular Degeneration, Central Visual Impairment
- Interventions
- 'Scotoma awareness' Training, Control Training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetic Macular Edema
- Interventions
- LKA651, Lucentis
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
- Conditions
- AMD
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Miami, Florida • Atlanta, Georgia + 11 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- Avacincaptad Pegol, Sham
- Drug
- Lead sponsor
- IVERIC bio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 96
- States / cities
- Beverly Hills, California • Campbell, California • Fresno, California + 86 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Palomid 529
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Age-Related Macular Degeneration
- Interventions
- DE-120
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Bakersfield, California • Beverly Hills, California • Dallas, Texas
- Conditions
- Age Factor, Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- ORA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Diabetic Retinopathy
- Interventions
- Laser Treatment
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 223 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina • Houston, Texas
- Conditions
- Age-Related Maculopathy
- Interventions
- Rheopheresis
- Device
- Lead sponsor
- OccuLogix
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Biological
- Lead sponsor
- Xbrane Biopharma AB
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration, Wet Age-Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Houston, Texas • The Woodlands, Texas
- Conditions
- Wet Age Related Macular Degeneration, wAMD
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more